Subclinical hypothyroidism and vascular risk: an update

Area of Science:

• Endocrinology
• Cardiovascular Medicine

Background:

• Subclinical hypothyroidism (SCH) is characterized by elevated thyroid-stimulating hormone (TSH) with normal free thyroxine (FT4) and triiodothyronine (T3).
• SCH is prevalent and associated with adverse lipid profiles and increased cardiovascular (CV) risk.
• Levothyroxine treatment is typically reserved for TSH levels >10 mIU/L.

Purpose of the Study:

• To review the impact of levothyroxine treatment on lipid profiles and CV risk markers in subclinical hypothyroidism.
• To explore the complex relationship between SCH, lipid metabolism, and vascular health.

Main Methods:

• Literature review of studies investigating levothyroxine's effects in SCH.
• Analysis of data on lipid profiles, carotid intima-media thickness (cIMT), endothelial function, and other CV risk predictors.

Main Results:

• Most studies indicate levothyroxine treatment favorably impacts lipid profiles, particularly total cholesterol and LDL-cholesterol in SCH.
• Evidence suggests potential improvements in CV risk markers like cIMT and endothelial function.
• Variability in results may stem from the complex interplay between SCH and vascular disease predictors.

Conclusions:

• Levothyroxine therapy may offer cardiovascular benefits in subclinical hypothyroidism by improving lipid profiles and other CV risk factors.
• Further intervention studies are necessary to definitively establish the clinical significance of levothyroxine treatment for CV risk reduction in SCH.